Improving Pharmaceutical Innovation by Building a More Comprehensive Database on Drug Development and Use (Health Affair: Feb 2015)

Gregory W. Daniel1,*, Alexis Cazé2, Morgan H. Romine3, Céline Audibert4, Jonathan S. Leff5 and Mark B. McClellan6

Author Affiliations

1Gregory W. Daniel ([email protected]) is a fellow and managing director for evidence development and innovation at the Engelberg Center for Health Care Reform at Brookings, in Washington, D.C.
2Alexis Cazé is managing director of the Deerfield Institute, in Epalinges, Switzerland.
3Morgan H. Romine is a research associate at the Engelberg Center for Health Care Reform at Brookings.
4Céline Audibert is director of European market research at the Deerfield Institute.
5Jonathan S. Leff is chairman of the Deerfield Institute, and a partner with Deerfield Management, in New York City.
6Mark B. McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at the Engelberg Center for Health Care Reform at Brookings.
↵*Corresponding author


New drugs and biologics have had a tremendous impact on the treatment of many diseases. However, available measures suggest that pharmaceutical innovation has remained relatively flat, despite substantial growth in research and development spending. We review recent literature on pharmaceutical innovation to identify limitations in measuring and assessing innovation, and we describe the framework and collaborative approach we are using to develop more comprehensive, publicly available metrics for innovation. Our research teams at the Brookings Institution and Deerfield Institute are collaborating with experts from multiple areas of drug development and regulatory review to identify and collect comprehensive data elements related to key development and regulatory characteristics for each new molecular entity approved over the past several decades in the United States and the European Union. Subsequent phases of our effort will add data on downstream product use and patient outcomes and will also include drugs that have failed or been abandoned in development. Such a database will enable researchers to better analyze the drivers of drug innovation, trends in the output of new medicines, and the effect of policy efforts designed to improve innovation.

Read the full text article on the Health Affairs website